AI In Drug Development: Avoid The ‘Flashiness,’ And Simply Ask ‘Does It Fit?’ – US FDA’s ElZarrad
Executive Summary
The Center for Drug Evaluation and Research’s medical policy chief says artificial intelligence can aid patient recruitment and increase trial diversity, but warned of “unique” potential pitfalls for sponsors.